A Parallel-Group Comparison of Two Doses Of Multihance (0.10 mmol/Kg and 0.05 mmol/Kg) When Used For Magnetic Resonance Imaging (MRI) of The Central Nervous System (CNS)
Phase of Trial: Phase IV
Latest Information Update: 17 Jul 2017
At a glance
- Drugs Gadobenic acid (Primary)
- Indications CNS disorders
- Focus Diagnostic use
- Sponsors Bracco Diagnostics
- 11 Jul 2017 Planned End Date changed from 1 Aug 2017 to 1 Dec 2017.
- 11 Jul 2017 Status changed from not yet recruiting to recruiting.
- 12 May 2017 New trial record